Innovation Is 'Our North Star’ Says Illumina Chief
Next-Generation Sequencing Group Eyeing Growing Role For Genomics In Infectious Disease
Executive Summary
The total addressable market for genomics infectious disease testing is increasing, says Illumina, after becoming the first company to receive a US EUA for a next generation sequencing-based COVID-19 test. It came amid a raft of innovation activity and tuck-in M&A for the San Diego group.
You may also be interested in...
First Test That Can Detect COVID-19 Virus Mutations Authorized By FDA
The US FDA on 10 June authorized use of Illumina’s COVIDSeq next generation sequencing diagnostic test to detect the SARS-CoV-2 virus and figure out if it’s mutating. The agency has high hopes this first-of-its-kind test will give researchers a better picture in the ongoing global fight against the COVID-19 pandemic.
DTx And Drug Deal Sees Closed Loop Medicine And Teva Team Up On Precision Care
Medicines are still typically prescribed based on average effects in a population and rarely dose-optimized for the individual, says Closed Loop Medicine. The company sees a new strategic partnership with Teva UK as another step in advancing personalized medicine.
Swiss-EU Standoff Set To End? Medtechs Eye MRA Action
Negotiations aimed at renewing the close trading relationship and barrier-free mutual market access between Switzerland and the EU got underway on 19 March. Swiss medtech companies welcomed the move, stressing the need for the defunct mutual recognition agreement to be updated.